APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Insulin Glargine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Long-acting Insulin Glargine Industry Growth and Trends Forecast to 2032

Report ID 174008820123 December 2025108 pages

Choose your research edition.

Industry ResearchLong-acting Insulin Glargine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Insulin Glargine Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Long-acting Insulin Glargine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Insulin Glargine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Insulin Glargine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Long-acting Insulin Glargine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Long-acting Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Long-acting Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long-acting Insulin Glargine include Biocare, Biocon Biologics, Cipla, INFION PHARMA, KALBE PHARMA, Lupin Laboratories, Swixx Biopharma, Viatris and Wockhardt, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Long-acting Insulin Glargine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Long-acting Insulin Glargine market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Long-acting Insulin Glargine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Long-acting Insulin Glargine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Long-acting Insulin Glargine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Long-acting Insulin Glargine Market by Company

Biocare

Biocon Biologics

Cipla

INFION PHARMA

KALBE PHARMA

Lupin Laboratories

Swixx Biopharma

Viatris

Wockhardt

Gan & Lee

Eli Lilly & Co

Sanofi

Tonghua Dongbao

United Laboratories

Long-acting Insulin Glargine Segment by Type

Vial

Prefilled

Long-acting Insulin Glargine Segment by Application

Type 2 Diabetes

Type 1 Diabetes

Long-acting Insulin Glargine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Insulin Glargine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Insulin Glargine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Insulin Glargine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long-acting Insulin Glargine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Long-acting Insulin Glargine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Vial Table 2. Major Company of Prefilled Table 3. Global Long-acting Insulin Glargine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Long-acting Insulin Glargine Sales by Type (2021-2026) & (k units) Table 5. Global Long-acting Insulin Glargine Sales Market Share in Volume by Type (2021-2026) Table 6. Global Long-acting Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 7. Global Long-acting Insulin Glargine Sales Market Share in Value by Type (2021-2026) Table 8. Global Long-acting Insulin Glargine Price by Type (2021-2026) & (USD/unit) Table 9. Global Long-acting Insulin Glargine Sales by Type (2027-2032) & (k units) Table 10. Global Long-acting Insulin Glargine Sales Market Share in Volume by Type (2027-2032) Table 11. Global Long-acting Insulin Glargine Sales by Type (2027-2032) & (US$ Million) Table 12. Global Long-acting Insulin Glargine Sales Market Share in Value by Type (2027-2032) Table 13. Global Long-acting Insulin Glargine Price by Type (2027-2032) & (USD/unit) Table 14. North America Long-acting Insulin Glargine Sales by Type (2021-2026) & (k units) Table 15. North America Long-acting Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Long-acting Insulin Glargine Sales by Type (2021-2026) & (k units) Table 17. Europe Long-acting Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Long-acting Insulin Glargine Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Long-acting Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Long-acting Insulin Glargine Sales by Type (2021-2026) & (k units) Table 21. Latin America Long-acting Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Long-acting Insulin Glargine Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Long-acting Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 24. Long-acting Insulin Glargine Industry Trends Table 25. Long-acting Insulin Glargine Industry Drivers Table 26. Long-acting Insulin Glargine Industry Opportunities and Challenges Table 27. Long-acting Insulin Glargine Industry Restraints Table 28. Global Long-acting Insulin Glargine Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Long-acting Insulin Glargine Revenue Market Share by Company (2021-2026) Table 30. Global Long-acting Insulin Glargine Sales by Company (2021-2026) & (k units) Table 31. Global Long-acting Insulin Glargine Sales Share by Company (2021-2026) Table 32. Global Long-acting Insulin Glargine Market Price by Company (2021-2026) & (USD/unit) Table 33. Global Long-acting Insulin Glargine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Long-acting Insulin Glargine Major Company Production Sites and Headquarters Table 35. Global Long-acting Insulin Glargine Company, Product Type & Application Table 36. Global Long-acting Insulin Glargine Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Long-acting Insulin Glargine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Long-acting Insulin Glargine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Long-acting Insulin Glargine Sales by Region (2021-2026) & (k units) Table 41. Global Long-acting Insulin Glargine Sales Market Share in Volume by Region (2021-2026) Table 42. Global Long-acting Insulin Glargine Sales by Region (2021-2026) & (US$ Million) Table 43. Global Long-acting Insulin Glargine Sales Market Share in Value by Region (2021-2026) Table 44. Global Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 45. Global Long-acting Insulin Glargine Sales by Region (2027-2032) & (k units) Table 46. Global Long-acting Insulin Glargine Sales Market Share in Volume by Region (2027-2032) Table 47. Global Long-acting Insulin Glargine Sales by Region (2027-2032) & (US$ Million) Table 48. Global Long-acting Insulin Glargine Sales Market Share in Value by Region (2027-2032) Table 49. Global Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2027-2032) Table 50. Global Long-acting Insulin Glargine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Long-acting Insulin Glargine Sales by Application (2021-2026) & (k units) Table 52. Global Long-acting Insulin Glargine Sales Market Share in Volume by Application (2021-2026) Table 53. Global Long-acting Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 54. Global Long-acting Insulin Glargine Sales Market Share in Value by Application (2021-2026) Table 55. Global Long-acting Insulin Glargine Price by Application (2021-2026) & (USD/unit) Table 56. Global Long-acting Insulin Glargine Sales by Application (2027-2032) & (k units) Table 57. Global Long-acting Insulin Glargine Sales Market Share in Volume by Application (2027-2032) Table 58. Global Long-acting Insulin Glargine Sales by Application (2027-2032) & (US$ Million) Table 59. Global Long-acting Insulin Glargine Sales Market Share in Value by Application (2027-2032) Table 60. Global Long-acting Insulin Glargine Price by Application (2027-2032) & (USD/unit) Table 61. North America Long-acting Insulin Glargine Sales by Application (2021-2026) & (k units) Table 62. North America Long-acting Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Long-acting Insulin Glargine Sales by Application (2021-2026) & (k units) Table 64. Europe Long-acting Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Long-acting Insulin Glargine Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Long-acting Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Long-acting Insulin Glargine Sales by Application (2021-2026) & (k units) Table 68. Latin America Long-acting Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Long-acting Insulin Glargine Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Long-acting Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 71. Biocare Company Information Table 72. Biocare Business Overview Table 73. Biocare Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 74. Biocare Long-acting Insulin Glargine Product Portfolio Table 75. Biocare Recent Development Table 76. Biocon Biologics Company Information Table 77. Biocon Biologics Business Overview Table 78. Biocon Biologics Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 79. Biocon Biologics Long-acting Insulin Glargine Product Portfolio Table 80. Biocon Biologics Recent Development Table 81. Cipla Company Information Table 82. Cipla Business Overview Table 83. Cipla Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 84. Cipla Long-acting Insulin Glargine Product Portfolio Table 85. Cipla Recent Development Table 86. INFION PHARMA Company Information Table 87. INFION PHARMA Business Overview Table 88. INFION PHARMA Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. INFION PHARMA Long-acting Insulin Glargine Product Portfolio Table 90. INFION PHARMA Recent Development Table 91. KALBE PHARMA Company Information Table 92. KALBE PHARMA Business Overview Table 93. KALBE PHARMA Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. KALBE PHARMA Long-acting Insulin Glargine Product Portfolio Table 95. KALBE PHARMA Recent Development Table 96. Lupin Laboratories Company Information Table 97. Lupin Laboratories Business Overview Table 98. Lupin Laboratories Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Lupin Laboratories Long-acting Insulin Glargine Product Portfolio Table 100. Lupin Laboratories Recent Development Table 101. Swixx Biopharma Company Information Table 102. Swixx Biopharma Business Overview Table 103. Swixx Biopharma Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Swixx Biopharma Long-acting Insulin Glargine Product Portfolio Table 105. Swixx Biopharma Recent Development Table 106. Viatris Company Information Table 107. Viatris Business Overview Table 108. Viatris Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Viatris Long-acting Insulin Glargine Product Portfolio Table 110. Viatris Recent Development Table 111. Wockhardt Company Information Table 112. Wockhardt Business Overview Table 113. Wockhardt Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Wockhardt Long-acting Insulin Glargine Product Portfolio Table 115. Wockhardt Recent Development Table 116. Gan & Lee Company Information Table 117. Gan & Lee Business Overview Table 118. Gan & Lee Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Gan & Lee Long-acting Insulin Glargine Product Portfolio Table 120. Gan & Lee Recent Development Table 121. Eli Lilly & Co Company Information Table 122. Eli Lilly & Co Business Overview Table 123. Eli Lilly & Co Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Eli Lilly & Co Long-acting Insulin Glargine Product Portfolio Table 125. Eli Lilly & Co Recent Development Table 126. Sanofi Company Information Table 127. Sanofi Business Overview Table 128. Sanofi Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Sanofi Long-acting Insulin Glargine Product Portfolio Table 130. Sanofi Recent Development Table 131. Tonghua Dongbao Company Information Table 132. Tonghua Dongbao Business Overview Table 133. Tonghua Dongbao Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Tonghua Dongbao Long-acting Insulin Glargine Product Portfolio Table 135. Tonghua Dongbao Recent Development Table 136. United Laboratories Company Information Table 137. United Laboratories Business Overview Table 138. United Laboratories Long-acting Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. United Laboratories Long-acting Insulin Glargine Product Portfolio Table 140. United Laboratories Recent Development Table 141. North America Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 142. North America Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 143. North America Long-acting Insulin Glargine Sales Market Share by Country (2021-2026) Table 144. North America Long-acting Insulin Glargine Sales Forecast by Country (2027-2032) & (k units) Table 145. North America Long-acting Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 146. North America Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. North America Long-acting Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 148. North America Long-acting Insulin Glargine Market Share by Country (2021-2026) Table 149. North America Long-acting Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. North America Long-acting Insulin Glargine Market Share Forecast by Country (2027-2032) Table 151. Europe Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 152. Europe Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 153. Europe Long-acting Insulin Glargine Sales Market Share by Country (2021-2026) Table 154. Europe Long-acting Insulin Glargine Sales Forecast by Country (2027-2032) & (k units) Table 155. Europe Long-acting Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 156. Europe Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Europe Long-acting Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 158. Europe Long-acting Insulin Glargine Market Share by Country (2021-2026) Table 159. Europe Long-acting Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Europe Long-acting Insulin Glargine Market Share Forecast by Country (2027-2032) Table 161. Asia-Pacific Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 162. Asia-Pacific Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 163. Asia-Pacific Long-acting Insulin Glargine Sales Market Share by Country (2021-2026) Table 164. Asia-Pacific Long-acting Insulin Glargine Sales Forecast by Country (2027-2032) & (k units) Table 165. Asia-Pacific Long-acting Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 166. Asia-Pacific Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Asia-Pacific Long-acting Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 168. Asia-Pacific Long-acting Insulin Glargine Market Share by Country (2021-2026) Table 169. Asia-Pacific Long-acting Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Asia-Pacific Long-acting Insulin Glargine Market Share Forecast by Country (2027-2032) Table 171. Latin America Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 172. Latin America Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 173. Latin America Long-acting Insulin Glargine Sales Market Share by Country (2021-2026) Table 174. Latin America Long-acting Insulin Glargine Sales Forecast by Country (2027-2032) & (k units) Table 175. Latin America Long-acting Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 176. Latin America Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Latin America Long-acting Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 178. Latin America Long-acting Insulin Glargine Market Share by Country (2021-2026) Table 179. Latin America Long-acting Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Latin America Long-acting Insulin Glargine Market Share Forecast by Country (2027-2032) Table 181. Middle East and Africa Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 182. Middle East and Africa Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 183. Middle East and Africa Long-acting Insulin Glargine Sales Market Share by Country (2021-2026) Table 184. Middle East and Africa Long-acting Insulin Glargine Sales Forecast by Country (2027-2032) & (k units) Table 185. Middle East and Africa Long-acting Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 186. Middle East and Africa Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Middle East and Africa Long-acting Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 188. Middle East and Africa Long-acting Insulin Glargine Market Share by Country (2021-2026) Table 189. Middle East and Africa Long-acting Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Middle East and Africa Long-acting Insulin Glargine Market Share Forecast by Country (2027-2032) Table 191. Key Raw Materials Table 192. Raw Materials Key Suppliers Table 193. Long-acting Insulin Glargine Distributors List Table 194. Long-acting Insulin Glargine Customers List Table 195. Research Programs/Design for This Report Table 196. Authors List of This Report Table 197. Secondary Sources Table 198. Primary Sources List of Figures Figure 1. Long-acting Insulin Glargine Image Figure 2. Global Long-acting Insulin Glargine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Insulin Glargine Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting Insulin Glargine Sales (2021-2032) & (k units) Figure 5. Vial Image Figure 6. Global Vial Sales YoY Growth (2021-2032) & (k units) Figure 7. Prefilled Image Figure 8. Global Prefilled Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Long-acting Insulin Glargine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Long-acting Insulin Glargine Market Share by Type 2025 VS 2032 Figure 11. North America Long-acting Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 12. North America Long-acting Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 13. Europe Long-acting Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 14. Europe Long-acting Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Long-acting Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Long-acting Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 17. Latin America Long-acting Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Long-acting Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Long-acting Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Long-acting Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Long-acting Insulin Glargine Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Type 2 Diabetes Image Figure 24. Global Type 2 Diabetes Sales YoY Growth (2021-2032) & (k units) Figure 25. Type 1 Diabetes Image Figure 26. Global Type 1 Diabetes Sales YoY Growth (2021-2032) & (k units) Figure 27. Global Long-acting Insulin Glargine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Long-acting Insulin Glargine Market Share by Application 2025 VS 2032 Figure 29. North America Long-acting Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 30. North America Long-acting Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 31. Europe Long-acting Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 32. Europe Long-acting Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Long-acting Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Long-acting Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 35. Latin America Long-acting Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Long-acting Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Long-acting Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Long-acting Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 39. North America Long-acting Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 40. North America Long-acting Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Long-acting Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Long-acting Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Long-acting Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. Europe Long-acting Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Long-acting Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Long-acting Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Long-acting Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Asia-Pacific Long-acting Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Long-acting Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Long-acting Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Long-acting Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Latin America Long-acting Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Long-acting Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Long-acting Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Long-acting Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Middle East and Africa Long-acting Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Long-acting Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Long-acting Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Long-acting Insulin Glargine Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Long-acting Insulin Glargine Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Vial
  • Prefilled
Applications
  • Type 2 Diabetes
  • Type 1 Diabetes
Companies covered
  • Biocare
  • Biocon Biologics
  • Cipla
  • INFION PHARMA
  • KALBE PHARMA
  • Lupin Laboratories
  • Swixx Biopharma
  • Viatris
  • Wockhardt
  • Gan & Lee
  • Eli Lilly & Co
  • Sanofi
  • Tonghua Dongbao
  • United Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long-acting Insulin Glargine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Long-acting Insulin Glargine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Long-acting Insulin Glargine Market by Type
  6. 1.3.1 Vial
  7. 1.3.2 Prefilled
  8. 1.4 Global Long-acting Insulin Glargine Market Size by Type
  9. 1.4.1 Global Long-acting Insulin Glargine Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Long-acting Insulin Glargine Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Long-acting Insulin Glargine Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Long-acting Insulin Glargine Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Long-acting Insulin Glargine Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Long-acting Insulin Glargine Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Long-acting Insulin Glargine Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Long-acting Insulin Glargine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Long-acting Insulin Glargine Industry Trends
  2. 2.2 Long-acting Insulin Glargine Industry Drivers
  3. 2.3 Long-acting Insulin Glargine Industry Opportunities and Challenges
  4. 2.4 Long-acting Insulin Glargine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Long-acting Insulin Glargine Revenue (2021-2026)
  2. 3.2 Global Top Players by Long-acting Insulin Glargine Sales (2021-2026)
  3. 3.3 Global Top Players by Long-acting Insulin Glargine Price (2021-2026)
  4. 3.4 Global Long-acting Insulin Glargine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long-acting Insulin Glargine Major Company Production Sites & Headquarters
  6. 3.6 Global Long-acting Insulin Glargine Company, Product Type & Application
  7. 3.7 Global Long-acting Insulin Glargine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long-acting Insulin Glargine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long-acting Insulin Glargine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long-acting Insulin Glargine Tier 1, Tier 2, and Tier 3
4 Long-acting Insulin Glargine Regional Status and Outlook
  1. 4.1 Global Long-acting Insulin Glargine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Long-acting Insulin Glargine Historic Market Size by Region
  3. 4.2.1 Global Long-acting Insulin Glargine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Long-acting Insulin Glargine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Long-acting Insulin Glargine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Long-acting Insulin Glargine Forecasted Market Size by Region
  7. 4.3.1 Global Long-acting Insulin Glargine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Long-acting Insulin Glargine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Long-acting Insulin Glargine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Long-acting Insulin Glargine by Application
  1. 5.1 Long-acting Insulin Glargine Market by Application
  2. 5.1.1 Type 2 Diabetes
  3. 5.1.2 Type 1 Diabetes
  4. 5.2 Global Long-acting Insulin Glargine Market Size by Application
  5. 5.2.1 Global Long-acting Insulin Glargine Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Long-acting Insulin Glargine Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Long-acting Insulin Glargine Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Long-acting Insulin Glargine Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Long-acting Insulin Glargine Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Long-acting Insulin Glargine Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Long-acting Insulin Glargine Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Long-acting Insulin Glargine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Biocare
  2. 6.1.1 Biocare Company Information
  3. 6.1.2 Biocare Business Overview
  4. 6.1.3 Biocare Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Biocare Long-acting Insulin Glargine Product Portfolio
  6. 6.1.5 Biocare Recent Developments
  7. 6.2 Biocon Biologics
  8. 6.2.1 Biocon Biologics Company Information
  9. 6.2.2 Biocon Biologics Business Overview
  10. 6.2.3 Biocon Biologics Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Biocon Biologics Long-acting Insulin Glargine Product Portfolio
  12. 6.2.5 Biocon Biologics Recent Developments
  13. 6.3 Cipla
  14. 6.3.1 Cipla Company Information
  15. 6.3.2 Cipla Business Overview
  16. 6.3.3 Cipla Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Cipla Long-acting Insulin Glargine Product Portfolio
  18. 6.3.5 Cipla Recent Developments
  19. 6.4 INFION PHARMA
  20. 6.4.1 INFION PHARMA Company Information
  21. 6.4.2 INFION PHARMA Business Overview
  22. 6.4.3 INFION PHARMA Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 INFION PHARMA Long-acting Insulin Glargine Product Portfolio
  24. 6.4.5 INFION PHARMA Recent Developments
  25. 6.5 KALBE PHARMA
  26. 6.5.1 KALBE PHARMA Company Information
  27. 6.5.2 KALBE PHARMA Business Overview
  28. 6.5.3 KALBE PHARMA Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 KALBE PHARMA Long-acting Insulin Glargine Product Portfolio
  30. 6.5.5 KALBE PHARMA Recent Developments
  31. 6.6 Lupin Laboratories
  32. 6.6.1 Lupin Laboratories Company Information
  33. 6.6.2 Lupin Laboratories Business Overview
  34. 6.6.3 Lupin Laboratories Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Lupin Laboratories Long-acting Insulin Glargine Product Portfolio
  36. 6.6.5 Lupin Laboratories Recent Developments
  37. 6.7 Swixx Biopharma
  38. 6.7.1 Swixx Biopharma Company Information
  39. 6.7.2 Swixx Biopharma Business Overview
  40. 6.7.3 Swixx Biopharma Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Swixx Biopharma Long-acting Insulin Glargine Product Portfolio
  42. 6.7.5 Swixx Biopharma Recent Developments
  43. 6.8 Viatris
  44. 6.8.1 Viatris Company Information
  45. 6.8.2 Viatris Business Overview
  46. 6.8.3 Viatris Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Viatris Long-acting Insulin Glargine Product Portfolio
  48. 6.8.5 Viatris Recent Developments
  49. 6.9 Wockhardt
  50. 6.9.1 Wockhardt Company Information
  51. 6.9.2 Wockhardt Business Overview
  52. 6.9.3 Wockhardt Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Wockhardt Long-acting Insulin Glargine Product Portfolio
  54. 6.9.5 Wockhardt Recent Developments
  55. 6.10 Gan & Lee
  56. 6.10.1 Gan & Lee Company Information
  57. 6.10.2 Gan & Lee Business Overview
  58. 6.10.3 Gan & Lee Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Gan & Lee Long-acting Insulin Glargine Product Portfolio
  60. 6.10.5 Gan & Lee Recent Developments
  61. 6.11 Eli Lilly & Co
  62. 6.11.1 Eli Lilly & Co Company Information
  63. 6.11.2 Eli Lilly & Co Business Overview
  64. 6.11.3 Eli Lilly & Co Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Eli Lilly & Co Long-acting Insulin Glargine Product Portfolio
  66. 6.11.5 Eli Lilly & Co Recent Developments
  67. 6.12 Sanofi
  68. 6.12.1 Sanofi Company Information
  69. 6.12.2 Sanofi Business Overview
  70. 6.12.3 Sanofi Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Sanofi Long-acting Insulin Glargine Product Portfolio
  72. 6.12.5 Sanofi Recent Developments
  73. 6.13 Tonghua Dongbao
  74. 6.13.1 Tonghua Dongbao Company Information
  75. 6.13.2 Tonghua Dongbao Business Overview
  76. 6.13.3 Tonghua Dongbao Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Tonghua Dongbao Long-acting Insulin Glargine Product Portfolio
  78. 6.13.5 Tonghua Dongbao Recent Developments
  79. 6.14 United Laboratories
  80. 6.14.1 United Laboratories Company Information
  81. 6.14.2 United Laboratories Business Overview
  82. 6.14.3 United Laboratories Long-acting Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 United Laboratories Long-acting Insulin Glargine Product Portfolio
  84. 6.14.5 United Laboratories Recent Developments
7 North America by Country
  1. 7.1 North America Long-acting Insulin Glargine Sales by Country
  2. 7.1.1 North America Long-acting Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Long-acting Insulin Glargine Sales by Country (2021-2026)
  4. 7.1.3 North America Long-acting Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Long-acting Insulin Glargine Market Size by Country
  6. 7.2.1 North America Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Long-acting Insulin Glargine Market Size by Country (2021-2026)
  8. 7.2.3 North America Long-acting Insulin Glargine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Long-acting Insulin Glargine Sales by Country
  2. 8.1.1 Europe Long-acting Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Long-acting Insulin Glargine Sales by Country (2021-2026)
  4. 8.1.3 Europe Long-acting Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Long-acting Insulin Glargine Market Size by Country
  6. 8.2.1 Europe Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Long-acting Insulin Glargine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Long-acting Insulin Glargine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Long-acting Insulin Glargine Sales by Country
  2. 9.1.1 Asia-Pacific Long-acting Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Long-acting Insulin Glargine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Long-acting Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Long-acting Insulin Glargine Market Size by Country
  6. 9.2.1 Asia-Pacific Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Long-acting Insulin Glargine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Long-acting Insulin Glargine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Long-acting Insulin Glargine Sales by Country
  2. 10.1.1 South America Long-acting Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Long-acting Insulin Glargine Sales by Country (2021-2026)
  4. 10.1.3 South America Long-acting Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Long-acting Insulin Glargine Market Size by Country
  6. 10.2.1 South America Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Long-acting Insulin Glargine Market Size by Country (2021-2026)
  8. 10.2.3 South America Long-acting Insulin Glargine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Long-acting Insulin Glargine Sales by Country
  2. 11.1.1 Middle East and Africa Long-acting Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Long-acting Insulin Glargine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Long-acting Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Long-acting Insulin Glargine Market Size by Country
  6. 11.2.1 Middle East and Africa Long-acting Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Long-acting Insulin Glargine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Long-acting Insulin Glargine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Long-acting Insulin Glargine Value Chain Analysis
  2. 12.1.1 Long-acting Insulin Glargine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Long-acting Insulin Glargine Production Mode & Process
  7. 12.2 Long-acting Insulin Glargine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Long-acting Insulin Glargine Distributors
  10. 12.2.3 Long-acting Insulin Glargine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst